HC Wainwright reaffirms Buy for Vanda Pharmaceuticals stock

Published on 10/07/2026 at 06:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vanda Pharmaceuticals stock had a EUR 4.04 prior close on October 5, 2026. Second-quarter revenue was USD 50.53 million.

VNDA, US9216591084, Illustration mit AI erstellt.

Vanda Pharmaceuticals (ISIN US9216591084) had a prior close of EUR 4.04 at Lang & Schwarz on October 5, 2026. HC Wainwright reaffirmed a Buy rating and a USD 20.00 price target for the company on October 5, according to MarketBeat.

HC Wainwright keeps a USD 20 target

MarketBeat reported that HC Wainwright maintained its Buy rating and USD 20.00 target, which represented 342.48 percent upside from the cited USD 4.52 prior exchange price. The comparison highlights the gap between the analyst view and Vanda's market valuation, rather than a change in the Lang & Schwarz euro reference.

Revenue growth meets a heavy loss

Vanda generated USD 50.53 million in second-quarter 2026 revenue and recorded a USD 62.51 million net loss, according to the company's second-quarter earnings call transcript carried by Yahoo Finance. Revenue declined 4.00 percent from the second quarter of 2025, while the net loss widened from USD 27.20 million.

The product mix was sharply divided. Fanapt net product sales rose 23.00 percent to USD 36.00 million in the second quarter, while HETLIOZ sales fell 66.00 percent to USD 5.60 million as generic competition reduced volume, the same transcript reported.

Pipeline milestones carry the risk

Vanda's 2026 revenue guidance remains USD 240.00 million to USD 290.00 million, with the USD 265.00 million midpoint implying 23.00 percent growth from fiscal year 2025. Management also said the company held USD 170.00 million in cash, cash equivalents and marketable securities as of June 30, 2026.

A separate release reported by StockTitan said Vanda presented three imsidolimab posters at the EADV annual meeting from September 30 through October 3, 2026. The earnings call also identified December 12, 2026 as the FDA target action date for imsidolimab, giving the pipeline a defined regulatory milestone.

EUR 4.04 prior close sets the base

The Lang & Schwarz data set showed a EUR 4.04 prior close for October 5, 2026. Nasdaq context put Vanda at USD 4.52 at 4:00 p.m. ET on October 6, 2026, against a 52-week range of USD 4.27 to USD 9.94, while the finance quote indicated a market capitalization of USD 271.8 million.

The further course of trading is shown by the continuously updated real-time quote of Vanda Pharmaceuticals stock.